01537nam 2200397Ia 450 991069886770332120090512123704.0(CKB)5470000002397187(OCoLC)320838766(EXLCZ)99547000000239718720090512d2006 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] supplemental guidance on testing for replication competent retrovirus in reroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectorsRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,[2006]i, 13 pages digital, PDF fileTitle from PDF title page (viewed on May, 12, 2009)."November 2006."Includes bibliographical references (pages 10-11).Guidance for industry Gene therapyUnited StatesTestingRetrovirusesUnited StatesClinical trialsUnited StatesGene therapyTesting.RetrovirusesClinical trialsCenter for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910698867703321Guidance for industry3434577UNINA